DUBLIN – French immunotherapy firms Orphan Synergy Europe (OSE) Pharma SA and Effimune SAS are pooling their resources in a stock-based transaction, with the aim of creating scale in a rapidly moving field. The deal values Nantes-based Effimune at €30.4 million (US$33.5 million), based on OSE's closing share price (PARIS:OSE) of €7.60 Wednesday. The combined company will be called OSE Immunotherapeutics SA.